Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab.
Kristine A FrerichsMarloes E C BroekmansJhon A Marin SotoBerris van KesselMartijn W HeymansLisa C HolthofChristie P M VerkleijRengasamy BoominathanBhavesh VaidyaJocelyn SendeckiAmy AxelFrancois GaudetKodandaram PillarisettiSonja ZweegmanHomer C AdamsTuna MutisNiels W C J van de DonkPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
JNJ-7957 effectively kills MM cells ex vivo, including those from heavily pretreated MM patients, whereby several components of the immunosuppressive BM microenvironment had only modest effects on its killing capacity. Our findings support the ongoing trial with JNJ-7957 as single agent and provide the preclinical rationale for evaluating JNJ-7957 in combination with daratumumab in MM.
Keyphrases
- multiple myeloma
- end stage renal disease
- ejection fraction
- chronic kidney disease
- induced apoptosis
- clinical trial
- stem cells
- cell therapy
- peritoneal dialysis
- prognostic factors
- study protocol
- randomized controlled trial
- patient reported outcomes
- cell proliferation
- phase ii
- mesenchymal stem cells
- oxidative stress
- signaling pathway
- combination therapy
- smoking cessation
- replacement therapy